Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website https://www.jocmr.org

Review

Volume 15, Number 4, April 2023, pages 200-207

Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review

Tables

Table 1. Okuda Staging System, Developed to Estimate the Survival in HCC
 
Criteria01
HCC: hepatocellular carcinoma.
Tumor size> 50%< 50%
AscitesClinically detectableClinically absent
Albumin< 3 g/dL> 3 g/dL
Bilirubin> 3 mg/dL< 3 mg/dL
Stage
  I0
  II1 or 2
  III3 or 4

 

Table 2. Cancer of the Liver Italian Program Scoring System for HCC, Useful for Prognostication of HCC Patients Receiving Non-Surgical Treatment
 
VariableScore
HCC: hepatocellular carcinoma.
Child-Pugh stage
  A0
  B1
  C2
Tumor morphology
  Uninodular and extension ≤ 50%0
  Multinodular and extension ≤ 50%1
  Massive or extension > 50%2
Alpha-fetoprotein
  < 4000
  ≥ 4001
Portal vein thrombosis
  No0
  Yes1

 

Table 3. The Barcelona Classification for Staging and Treatment Strategy, Useful for Patients Undergoing Surgical Resection of HCC
 
StageDescription
HCC: hepatocellular carcinoma.
Early stage (0)A solitary, ≤ 2 cm tumor in a patient with preserved liver function, no symptoms suggestive of malignancy, and no vascular invasion or extrahepatic dissemination.
Early stage (A)Single tumor of any size or up to three nodules of less than 3 cm, with no macrovascular invasion, and no cancer-related symptoms.
Intermediate stage (B)Patients with multifocal HCC who have a performance status of zero and adequate liver function without invasion or spread.
Advanced stage (C)Presence of vascular invasion and extrahepatic spread, taking into consideration a performance status ≤ 2 and preserved liver function.
End stage (D)Patients with a performance status of more than 2 with cancer symptomatology and/or impaired liver function without an option for liver transplantation.